Success Metrics

Clinical Success Rate
100.0%

Based on 2 completed trials

Completion Rate
100%(2/2)
Active Trials
1(20%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_3
1
20%
Ph not_applicable
2
40%

Phase Distribution

0

Early Stage

0

Mid Stage

1

Late Stage

Phase Distribution3 total trials
Phase 3Large-scale testing
1(33.3%)
N/ANon-phased studies
2(66.7%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

66.7%

2 of 3 finished

Non-Completion Rate

33.3%

1 ended early

Currently Active

1

trials recruiting

Total Trials

5

all time

Status Distribution
Active(1)
Completed(2)
Terminated(1)
Other(1)

Detailed Status

Completed2
Recruiting1
unknown1
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
1
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 31 (33.3%)
N/A2 (66.7%)

Trials by Status

recruiting120%
unknown120%
completed240%
withdrawn120%

Recent Activity

1 active trials
Showing 5 of 5
recruitingphase_3

A Pivotal Clinical Trial of Human Induced Pluripotent Stem Cell-derived Cardiomyocytes Injection (HiCM-188) for the Treatment of Advanced Heart Failure(NYHA III-IV)

NCT07496372
completed

Incidence and Risk Factors of Surgical Site Infections After Coronary Artery Bypass Grafting Surgery

NCT07130422
withdrawnnot_applicable

Ventricular Sling for Heart Failure With Reduced Ejection Fraction

NCT04475315
completednot_applicable

Autologous Atrial Appendage Derived Cells in the Treatment of Heart Failure

NCT02672163
unknown

Current Treatment Strategy of Patients With Multivessel Disease or Left Main Coronary Artery Disease Indicated for Coronary Artery Bypass Graft Surgery

NCT02410993

Clinical Trials (5)

Showing 5 of 5 trials
NCT07496372Phase 3

A Pivotal Clinical Trial of Human Induced Pluripotent Stem Cell-derived Cardiomyocytes Injection (HiCM-188) for the Treatment of Advanced Heart Failure(NYHA III-IV)

Recruiting
NCT07130422

Incidence and Risk Factors of Surgical Site Infections After Coronary Artery Bypass Grafting Surgery

Completed
NCT04475315Not Applicable

Ventricular Sling for Heart Failure With Reduced Ejection Fraction

Withdrawn
NCT02672163Not Applicable

Autologous Atrial Appendage Derived Cells in the Treatment of Heart Failure

Completed
NCT02410993

Current Treatment Strategy of Patients With Multivessel Disease or Left Main Coronary Artery Disease Indicated for Coronary Artery Bypass Graft Surgery

Unknown

All 5 trials loaded

Drug Details

Intervention Type
PROCEDURE
Total Trials
5